Dr Virginia Gretton has joined ReFaC, the REACH Facilitiation Company based in Crewe, Cheshire, UK, as technical officer.
Gretton was formerly regulatory manager at Harlan Laboratories, Derbyshire, where she was involved with all aspects of REACH registration and compliance. This covered data gap analysis, testing plans, exposure scenarios, risk assessment, classification and labelling, downstream user interaction, Safety Data Sheet preparation, as well as post-registration support.
In addition, Dr Gretton has held posts in academia and managed clinical research projects. She holds a DPhil in chemistry from the University of York, a BSc in combined science, and a post-graduate certificate in REACH management.
Peter Newport, ReFaC’s company secretary, said: ‘Virginia brings a wealth of practical regulatory experience, skills and technical knowledge to her new role, which will be invaluable in helping and advising clients on all aspects of REACH compliance.’
ReFaC hires Dr Virginia Gretton as technical officer
Has experience with all aspects of REACH registration
You may also like
Regulatory
UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead
The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Regulatory
Lonza Nominates Stephen Fry as Independent Board Member
Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Regulatory
Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors
The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with haemophilia A or B who have developed inhibitors to factor replacement therapies
Regulatory
NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer
MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades